Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

733370.pdf (454.88 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-04-18

Llicència de publicació

cc-by (c) Vilaplana Carnerero, Carles et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/196964

Atherosclerosis, Cardiovascular Disease, and COVID‐19: A Narrative Review

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/biomedicines11041206

Resum

Atherosclerosis is a chronic inflammatory and degenerative process that mainly occurs in large‐ and medium‐sized arteries and is morphologically characterized by asymmetric focal thickenings of the innermost layer of the artery, the intima. This process is the basis of cardiovascular diseases (CVDs), the most common cause of death worldwide. Some studies suggest a bidirectional link between atherosclerosis and the consequent CVD with COVID‐19. The aims of this narrative review are (1) to provide an overview of the most recent studies that point out a bidirectional relation between COVID‐19 and atherosclerosis and (2) to summarize the impact of cardiovascular drugs on COVID‐19 outcomes. A growing body of evidence shows that COVID‐19 prognosis in individuals with CVD is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with CVD after COVID‐19. The most common treatments for CVD may influence COVID‐19 outcomes. Thus, their implication in the infection process is briefly discussed in this review. A better understanding of the link among atherosclerosis, CVD, and COVID‐19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.

Matèries

COVID-19, Aterosclerosi, Malalties cardiovasculars, Factors de risc en les malalties, Pronòstic mèdic

Matèries (anglès)

COVID-19, Atherosclerosis, Cardiovascular diseases, Risk factors in diseases, Prognosis

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VILAPLANA CARNERERO, Carles, et al. Atherosclerosis, Cardiovascular Disease, and COVID‐19: A Narrative Review. Biomedicines. 2023. Vol. 11, num. 4, pags. 1206. ISSN 2227-9059. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/196964

Exportar metadades

JSON - METS

Compartir registre